Personalized genetic prediction: too limited, too expensive, or too soon?

the University of Ioannina, Iaonnina 45110, Greece.
Annals of internal medicine (Impact Factor: 16.1). 02/2009; 150(2):139-41. DOI: 10.7326/0003-4819-150-2-200901200-00012
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: High-throughput sequencing data can be used to predict phenotypes from genotypes, and this corresponds to establishing a prognostic model. In extended pedigrees the relatedness of subjects provides additional information so that genetic values, fixed or random genetic components, and heritability can be estimated. At the Genetic Analysis Workshop 18, the working group on genetic prediction dealt with both establishing a prognostic model and, in one contribution, comparing standard logistic regression with robust logistic regression in a sample of unrelated affected or unaffected individuals. Results of both logistic regression approaches were similar. All other contributions to this group used extended family data, in general using the quantitative trait blood pressure. The individual contributions varied in several important aspects, such as the estimation of the kinship matrix and the estimation method. Contributors chose various approaches for model validation, including different versions of cross-validation or within-family validation. Within-family validation included model building in the upper generations and validation in later generations. The choice of the statistical model and the computational algorithm had substantial effects on computation time. If decorrelation approaches were applied, the computational burden was substantially reduced. Some software packages estimated negative eigenvalues, although eigenvalues of correlation matrices should be non-negative. Most statistical models and software packages have been developed for experimental crosses and planned breeding programs. With their specialized pedigree structures, they are not sufficiently flexible to accommodate the variability of human pedigrees in general, and improved implementations are required.
    Genetic Epidemiology 09/2014; 38 Suppl 1:S57-62. DOI:10.1002/gepi.21826 · 2.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Psychiatric treatment relies on a solid armamentarium of pharmacologic and nonpharmacologic treatment modalities that perform reasonably well for many patients but leave others in a state of chronic disability or troubled by problematic side effects. Treatment planning in psychiatry remains an art that depends on considerable trial and error. Thus, there is an urgent need for better tools that will provide a means for matching individual patients with the most effective treatments while minimizing the risk of adverse events. This review will consider the current state of the science in predicting treatment outcomes in psychiatry. Genetic and other biomarkers will be considered alongside clinical diagnostic, and family history data. Problems inherent in prediction medicine will also be discussed, along with recent developments that support the hope that psychiatry can do a better job in quickly identifying the best treatments for each patient.
    Dialogues in clinical neuroscience 12/2014; 16(4):455-64.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This Pulmonary Perspective summarizes the content and main conclusions of an international workshop on personalized respiratory medicine co-organized by the Barcelona Respiratory Network ( and the AJRCCM in June 2014. It discusses: (1) its definition, historical, social, legal and ethical aspects; (2) the view from different disciplines, including basic science, epidemiology, bioinformatics and network/systems medicine.; (3) the bottlenecks and opportunities identified by some currently ongoing projects; and, (4) the implications for the individual, the health-care system and the pharmaceutical industry. Authors hope that, albeit not a systematic review on the subject, this document can be a useful reference for researchers, clinicians, health-care managers, policy-makers, and industry parties interested in personalized respiratory medicine.
    American Journal of Respiratory and Critical Care Medicine 12/2014; DOI:10.1164/rccm.201410-1935PP · 11.99 Impact Factor